MEDIPHARM LABS CORP. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.08 CAD | +6.67% |
|
0.00% | +23.08% |
| May. 15 | Transcript : MediPharm Labs Corp., Q1 2024 Earnings Call, May 15, 2024 | |
| May. 15 | MediPharm Labs Q1 Gross Profit, Rise | MT |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the past twelve months, EPS forecast has been revised upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +23.08% | 23.77M | D | ||
| +41.06% | 6.26B | B- | ||
| -15.95% | 4.49B | C+ | ||
| +6.36% | 3.29B | C | ||
| -11.34% | 3.12B | B- | ||
| -3.12% | 2.5B | - | D+ | |
| +45.41% | 1.94B | - | ||
| -7.74% | 1.68B | - | - | |
| -0.67% | 1.63B | - | - | |
| -11.32% | 1.56B | C- |
Investor Rating
Trading Rating
-
ESG Refinitiv
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- LABS Stock
- Ratings MediPharm Labs Corp.